179 related articles for article (PubMed ID: 37358877)
1. Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.
Smyth EN; John J; Tiu RV; Willard MD; Beyrer JK; Bowman L; Sheffield KM; Han Y; Brastianos PK
Oncologist; 2023 Nov; 28(11):e1075-e1091. PubMed ID: 37358877
[TBL] [Abstract][Full Text] [Related]
2. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
[TBL] [Abstract][Full Text] [Related]
3. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
[TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
[TBL] [Abstract][Full Text] [Related]
5. Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
He J; Pericone CD; Vanderpoel J
Adv Ther; 2022 Jul; 39(7):3347-3360. PubMed ID: 35674970
[TBL] [Abstract][Full Text] [Related]
6. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE).
Bennouna J; Falchero L; Schott R; Bonnetain F; Coudert M; Ben Hadj Yahia B; Chouaid C
Oncology; 2018; 94(1):55-64. PubMed ID: 29065416
[TBL] [Abstract][Full Text] [Related]
8. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
Hardtstock F; Myers D; Li T; Cizova D; Maywald U; Wilke T; Griesinger F
BMC Cancer; 2020 Mar; 20(1):260. PubMed ID: 32228520
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
11. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
[TBL] [Abstract][Full Text] [Related]
12. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
14. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N
J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Ahn BC; Lee S; Lee J; Lee JB; Hong MH; Lim SM; Jain S; Olsen S; Cho BC
Cancer Treat Res Commun; 2023; 36():100715. PubMed ID: 37307681
[TBL] [Abstract][Full Text] [Related]
18. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
20. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]